ARS Pharmaceuticals (SPRY) Non-Current Deffered Revenue (2021 - 2026)

ARS Pharmaceuticals has disclosed Non-Current Deffered Revenue across 5 years of filings, most recently posting $978000.0 for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $978000.0, down 26.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $978000.0 (down 26.96% YoY), and the FY2025 annual result was $1.1 million, down 26.24% from the prior year.
• Non-Current Deffered Revenue came in at $978000.0 for Q1 2026 at ARS Pharmaceuticals, down from $1.1 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $2.9 million in Q4 2022 to a low of $978000.0 in Q1 2026.
• The 4-year median for Non-Current Deffered Revenue is $1.3 million (2025), against an average of $1.5 million.
• Across the five-year window, Non-Current Deffered Revenue slipped 4.74% in 2022 and slipped 26.96% in 2026, its largest moves.
• ARS Pharmaceuticals' Non-Current Deffered Revenue stood at $2.9 million in 2022, then sank by 46.32% to $1.5 million in 2024, then decreased by 26.24% to $1.1 million in 2025, then decreased by 13.45% to $978000.0 in 2026.
• The last three Non-Current Deffered Revenue figures came in at $978000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.